X

Shilpa Medicare Ltd. Stock Analysis

Small Cap
Evaluated by 1902 users | BSE: 530549 | NSE: SHILPAMED |
Pharmaceuticals & Drugs
Shilpa Medicare, established in 1987, has carved a niche for itself in the exceedingly competitive and quality-conscious sphere of pharmaceuticals manufacturing. It produces and exports consistently high-quality Active Pharmaceutical Ingredients Fine Chemicals, intermediates, herbal products...

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Shilpa Medicare Ltd. has performed well in majority of the past ten years indicating its past ten year financial track record is very good
Value Creation
 Mar'11Mar'12Mar'13Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20
Return on Capital Employed 20.69%14.24%12.07%17.11%11.78%14.82%10.84%7.26%6.77%9.55%
Growth Parameters
Growth Parameters Colour Code Guide
Net Sales (Rs. Cr.) 290318371571614716779789733908
Y-o-Y Gr. Rt.-9.6%16.7%53.9%7.4%16.7%8.8%1.2%-7%23.8%
Adjusted EPS (Rs.) 6.365.826.3611.139.3713.8912.9610.8810.7117.73
Y-o-Y Gr. Rt.--8.5%9.3%75%-15.8%48.2%-6.7%-16.1%-1.6%65.6%
Book Value per Share (Rs.) 30.3337.4743.5253.8670.9282.91123.17133.09146.89163.06
Adjusted Net Profit 45.842.846.881.972.210710488.787.3145
Net Op. Cash Flow (Rs. Cr.) 40.956.743.67068.812937.544.9147124
Debt to Cash Flow from Ops 1.391.073.011.692.740.76.444.251.323.15
Standalone financials take only the parent company into account while consolidated financials take into account financials of the parent company as well as of all its subsidiaries. In most companies consolidated financials should be used for analysis.
Shilpa Medicare Ltd. should be analysed on a Consolidated basis
CAGR
CAGR Colour Code Guide
  9 yrs 5 yrs 3 yrs 1 yr
Net Sales 13.5%8.1%5.2%23.8%
Adjusted EPS 12.1%13.6%11%65.6%
Book Value per Share 20.618.19.811
Share Price 27.2% 0.1% -10% 57.7%
Key Financial Parameter
Performance Ratio Colour Code Guide
 Mar'11Mar'12Mar'13Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20
Return on Equity (%) 28.2217.1115.722.8415.3118.0612.788.567.6511.44
Operating Profit Margin (%) 24.3220.1118.5421.3420.622.5420.7519.1921.0623.63
Net Profit Margin (%) 15.8213.4212.6414.2311.614.6613.7211.8512.6215.79
Debt to Equity 0.260.220.410.30.340.140.240.180.160.29
Working Capital Days 117133151135158158193237266229
Cash Conversion Cycle 49494440565984116141126
Corporate Governance What do we look at?
Corporate Governance
Board Credentials
Promoter's holding
Transparency
Integrity
Entity Percentage Holding
Promoters 53.25%
Institutions 19.48%
Non-Institutions 27.27%
Pledged *9.6410.2810.0411.919.299.889.7710.2610.260.81
* Pledged shares as % of Promoter's holding (%)

MoneyWorks4Me analysed the past 10-year performance of Shilpa Medicare Ltd. and arrived at the following conclusion:

Past 10 year's financial track record indicates that Shilpa Medicare Ltd. is a good quality company. However, for specific investment actions please connect with your investment advisor.

The 5-year analysis of Shilpa Medicare Ltd.'s performance infers:

Shilpa Medicare Ltd. earnings have grown by 13.6%, whereas share price has appreciated 0.1% CAGR over the past five years, indicating the company's share price is likely undervalued. However, for specific investment actions please connect with your investment advisor.

We analysed the performance of Shilpa Medicare Ltd. share prices over the last 10 years. Here is what we found out:

Shilpa Medicare Ltd. share price has appreciated 16.8% annually over the past ten years.

Shilpa Medicare, established in 1987, has carved a niche for itself in the exceedingly competitive and quality-conscious sphere of pharmaceuticals manufacturing. It produces and exports consistently high-quality Active Pharmaceutical Ingredients Fine Chemicals, intermediates, herbal products and speciality chemical products using sophisticated technology, meticulously following international specifications.  

The company has earned its spurs as a successful and reliable partner

Shilpa Medicare, established in 1987, has carved a niche for itself in the exceedingly competitive and quality-conscious sphere of pharmaceuticals manufacturing. It produces and exports consistently high-quality Active Pharmaceutical Ingredients Fine Chemicals, intermediates, herbal products and speciality chemical products using sophisticated technology, meticulously following international specifications.  

The company has earned its spurs as a successful and reliable partner within the pharmaceutical industry. Buyers within the country and from across the borders count on its fast track integrated process development and finely honed expertise of its skilled and experienced personnel. The company is already exporting to USA, Canada, Australia, Japan and European countries viz., Germany, Switzerland, Netherlands, Belgium, Spain, Greece, Cyprus, Italy, United Kingdom etc., South American countries like Mexico, Brazil, Columbia etc, African countries like Kenya, Nigeria and West Indies etc, Asian countries like Singapore, Taiwan, China, Malaysia, Thailand and closer to home to Iran, Egypt, Pakistan and Bangladesh.  Shilpa Medicare is synergizing strength through tie-ups for manufacturing products and co-marketing rights, for it believes in working together and sharing success.

Being proactive in approach, the company continually seeks out enquiry’s for development of new products drawing from the extensive knowledge-base of its qualified and experienced people as well as sophisticated facilities.

Product range of the company includes:

Oncology AP's

  • Anastrozole 
  • Bicalutamide 
  • Carboplatin 
  • Gemcitabine HCI
  •  Irinotecan HCl Trihydrate
  • Oxaliplatin 
  • Temozolomide 
  • Cisplatin 
  • 5-Fluoro
  • Bortezomib 
  • Capecitabine 
  • Decarbazine 
  • Docetaxel 
  • Gefitinib 
  • Hydroxy urea 
  • Imatinib Mesylate 
  • Lenalidomide 
  • Letrozole
  • Methotrexate 
  • Thalidomide 
  • Topotecan HCl
  • Zoledronic acid 

General APIs

  • Ambroxol HCl 
  • Ticlopidine HCl 
  • Buflomedil HCl 
  • Nifedipine 
  • Lamivudine 
  • Sildenafil Citrate 
  • Terfenadine 
  • Acebrophylline 
  • Phenylephrine HCl 
  • Ursodeoxycholic acid 

PRODUCTS UNDER DEVELOPMENT (Oncology)

  •  Bendamustine Cladribine
  •  Decitabine Disodium Pamidronate
  •  Epirubicin Exemustane
  •  Fludarabine Phosphate  Idarubicine
  •  Paclitaxel  Pemetrexed
  •  Lomustine  Methotrexate
  •  Pamidronic acid  Tandutinib 

NUTRITIONAL SUPPLEMENTS 

  • Chromium picolinate  Chromium polynicotinate   

DRUG INTERMEDIATES

  • Trans-4-amino cyclohexanol
  • 2-Amino-3,5-dibromobenzaldehyde
  • 1,3,5-Trimethoxy Benzene 
  • 1,3,5-Tribromo Benzene
  • 7-ethyl camptothecin 
  • 7-ethyl-10-hydroxy camptothecin

Awards & Achievements:

  • Karnataka State Govt. 'Best Enterpreneur Award'.
  • Govt. of India 'Best Enterpreneur Award'.
  • ‘Star Export House’ Status from Ministry of Commerce and Industry, Govt. of India
  • 'cGMP' Certificates from W.H.O. for 20 API's
  • 'Best Export Award' from Visvesvaraya Industrial Trade Centre, Bangalore, Govt. of Karnataka,  INDIA
  • 'Outstanding Industrial Award' from Indian Junior Chamber.
  • 'Registration with 'Russian Health Authority' for Ambroxol HCl
  • 'Certificate of Suitability' received from EDQM for Ambroxol HCl (R0-CEP 2004-201-Rev 00)
  • 'Certificate of Suitability' received from EDQM for Ticlopidine HCl (R0-CEP 2005-004-Rev 00)
  • 'Certificate of Suitability' received from EDQM for Carboplatin (R0-CEP 2006-212-Rev 00)
  • Patent application on Irinotecan HCl Trihydrate 'An improved process for the preparation of Irinotecan HCl Trihydrate' published as WO2006016203 on date 2006-02-16
  • Patent file for Gemcitabine HCl and Anastrozole manufacturing process.
  • Filed ASMF/EDMF of Gemcitabine HCl over 21 EU countries
  • Filed ASMF/EDMF of Irinotecan HCl Trihydrate HCl over 27 EU countries
  • Filed ASMF/EDMF of Oxaliplatin HCl over 11 EU countries
  • 'Best District Export Award' received from FKCCI, Bangalore on 16.06.2007
  • Korean FDA Approved for Gemcitabine HCl & Ambroxol HCl
  • COS received from EDQM for Buflomedil HCl (R0-CEP 2006-080-Rev.00)
  • COS received from EDQM for Oxaliplatin EP (R0-CEP 2006-201-Rev.00)
  • 'Best District Export Award' received from FKCCI, Bangalore on 20.06.2008.
  • COS received from EDQM for Gemcitabine HCl EP (R0-CEP 2006-222-Rev 00)
  • 2010 - Shilpa Medicare Limited was granted certificate of GMP Compliance of Manufacturer for Gemcitabine Hydrochloride
  • 2012 - Shilpa Medicare Ltd has been conferred First Prize of the National Energy Conservation Award-2012 in the Drugs & Pharmaceuticals Sector from Ministry of Power, New Delhi.
Puchho Befikar
SEBI Registered: Investment Adviser - INA000013323

Callback